Glenmark's Win: NPPA revises price of Telmisartan, Cilnidipine FDC after data review
Glenmark
New Delhi: Drug maker, Glenmark Pharmaceuticals' appeal against the earlier price fixation for its cardiovascular drug combination, Cilnidipine 20 mg and Telmisartan 40 mg, has seen daylight as the National Pharmaceutical Pricing Authority (NPPA) recently revised the draft working sheet for the retail price of the said formulation.
Glenmark markets the combination drug Cilnidipine 20 mg and Telmisartan 40 mg under the brand name Telmi-C. This combination is used to treat hypertension (high blood pressure), helping to lower blood pressure and reduce the risk of cardiovascular events such as heart attacks, strokes, and kidney damage.
The Authority’s decision to revise the retail price of Glenmark’s cardiovascular drug combination was followed by a review order issued by the Department of Pharmaceuticals (DoP) in October, directing the NPPA to reconsider the pricing.
Glenmark had contested the price of Rs 12.83 per tablet, set in March 2023, citing errors in the Price to Retailer (PTR) data for Ajanta Pharma’s Cinod T, a competing product. Glenmark highlighted that the PTR for Cinod T had been incorrectly recorded as Rs 148.57 instead of Rs 200, leading to an undervaluation in the price calculation.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.